Recommended Adult Dose of Fenofibrate
For lowering triglycerides and raising HDL-cholesterol, the recommended adult dose of fenofibrate is 160 mg once daily taken with meals, with an initial dose of 54-160 mg daily for severe hypertriglyceridemia, titrated based on response at 4-8 week intervals. 1
Dosing Algorithm
Standard Dosing for Mixed Dyslipidemia or Primary Hypercholesterolemia
- Start: 160 mg once daily with meals 1
- This is the FDA-approved initial dose for patients with primary hypercholesterolemia or mixed dyslipidemia
- Taking with meals optimizes bioavailability 1
Severe Hypertriglyceridemia Dosing
- Start: 54-160 mg once daily 1
- Individualize based on patient response
- Recheck lipids at 4-8 week intervals and adjust accordingly 1
- Maximum dose: 160 mg once daily 1
Dose Adjustments for Special Populations
Renal Impairment:
- Mild to moderate renal dysfunction (eGFR 30-59 mL/min/1.73m²): Start at 54 mg daily 1
- Increase only after evaluating renal function and lipid response at this lower dose
- Severe renal impairment: Avoid fenofibrate 1
Elderly Patients:
- Base dose selection on renal function 1
- Many elderly patients will require the reduced 54 mg starting dose due to age-related decline in kidney function
Expected Lipid Effects
At the 160 mg daily dose, fenofibrate produces:
- Triglyceride reduction: 29-55% (greater reductions with higher baseline levels) 1
- HDL-cholesterol increase: 11-23% 1
- LDL-cholesterol reduction: 20-31% (in patients with elevated LDL) 1
The most dramatic effects occur in patients with severe hypertriglyceridemia (baseline TG 500-1500 mg/dL), where reductions of 46-55% are typical 1.
Monitoring and Duration
- Reassess lipids after 2 months at maximum dose 1
- Discontinue if inadequate response after 2 months at 160 mg daily 1
- Consider dose reduction if lipid levels fall significantly below target range 1
Critical Safety Considerations
When combining with statins (common in clinical practice):
- Keep statin doses relatively low to minimize myopathy risk 2
- The combination increases risk of severe myopathy 2
- Monitor for muscle symptoms and check CK if symptomatic
- Fenofibrate is preferred over gemfibrozil when combining with statins due to lower drug interaction potential
Contraindications to higher doses:
- Triglycerides >200 mg/dL: bile acid sequestrants are relatively contraindicated 2
- Patients should avoid alcohol when triglycerides are very high 2
Clinical Context from Guidelines
While guidelines from 2003-2013 2, 3, 2, 4 recommend fibrates (including fenofibrate) as therapeutic options for low HDL (<40 mg/dL) and elevated triglycerides (>200 mg/dL) after LDL-lowering therapy, more recent 2013-2014 ACC/AHA guidelines 5 found that fenofibrate added to simvastatin did not reduce cardiovascular events in the overall diabetic population, though a subgroup with triglycerides ≥204 mg/dL and HDL ≥40 mg/dL may have benefited.
The primary indication remains severe hypertriglyceridemia (≥500 mg/dL) to prevent pancreatitis 2, where fenofibrate demonstrates clear benefit with 46-55% triglyceride reductions 1.